Home › Funds › Caligan Partners LP › MBX

Caligan Partners LP position in MBX

MBX BIOSCIENCES INC COM · Health Care

Caligan Partners LP reported holding 200,000 shares of MBX (MBX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$11.0M, representing 0.65% of its reported portfolio and ranking #22 among its reported holdings. Caligan Partners LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)200.00K sh
Reported value held$11.04M
Portfolio Weight0.65%
First reportedQ1 2026
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Caligan Partners LP's MBX position evolved

Caligan Partners LP first disclosed a stake in MBX in Q1 2026 at 848,590 shares (US$25.3M). Across 2 filings, Caligan Partners LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 200,000 shares valued at US$11.0M — a reduction of -648,590 shares quarter over quarter.. Notable position changes include a 76% trim in Q2 2026 (shares rose 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 848.59K $25.33M New
Q2 2026 200.00K $11.04M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MBX and 13F data

MBX (MBX BIOSCIENCES INC COM) is a Health Care company. 73 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MBX

All MBX fund holders →

FAQ

How long has Caligan Partners LP held MBX?

Caligan Partners LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Caligan Partners LP's current position in MBX?

As of Q2 2026, Caligan Partners LP holds 200.00K shares of MBX (MBX BIOSCIENCES INC COM), valued at $11.04M, representing 0.65% of its reported portfolio and ranking #22.

Has Caligan Partners LP been buying or selling MBX?

In the latest 13F filing (Q2 2026), Caligan Partners LP reduced its position in MBX.

Which other funds hold MBX?

Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 73 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.